Osteopenia Clinical Trial
Official title:
Denosumab vs Zoledronate Efficacy in Osteopenic Patients With Lumbar Degenerative Disease After Lumbar Fusion Surgery
The aim of the study was to compare denosumab and zoledronate efficacy in bone mass, bone turnover markers (BTMs), Visual Analogue Scale (VAS) for leg and back, EuroQol Five-Dimension (EQ-5D) scores, Quality of Life Questionnaire of the European Foundation for Osteoporosis-31 (QUALEFFO-31) scores, and Roland-Morris Disability Functioning Questionnaire (RMDQ) scores, secondary fracture, complications and adverse events after lumbar fusion.
Status | Recruiting |
Enrollment | 100 |
Est. completion date | February 28, 2023 |
Est. primary completion date | February 26, 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 40 Years to 85 Years |
Eligibility | Inclusion Criteria: - Participants aged 40 to 85 years - who diagnosed with lumbar spinal stenosis or lumbar spondylolisthesis - osteopenia with BMD T score between -1 and -2.5 via dual energy X-ray - low back pain or leg numbness or weakness - MRI demonstrated signs of nerve compression - patients with one or two level symptoms. Exclusion Criteria: - cauda equina syndrome - progressive neurologic deficit - history of cancer - scoliosis greater than 15° - back open surgery history - have contraindications for surgery - who had anti-osteoporosis medication within 6 weeks |
Country | Name | City | State |
---|---|---|---|
China | ShenzhenPH | Shenzhen | Guangdong |
Lead Sponsor | Collaborator |
---|---|
Shenzhen People's Hospital |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Lumbar bone mineral density(BMD) | Lumbar vertebral (L1 to L4, except the surgery segment) BMD were determined at baseline, 6 and 12 months via dual energy X-ray | up to 12 months | |
Primary | Total hip BMD | Total hip BMD were determined at baseline, 6 and 12 months via dual-energy X-ray | up to 12 months | |
Primary | Femoral neck BMD | Femoral neck BMD were determined at baseline, 6 and 12 month via dual-energy X-ray | up to 12 months | |
Primary | Procollagen type 1 n-terminal propeptide (P1NP) | Bone formation marker, P1NP were determined at baseline, 6 and 12 months after surgery | up to 12 months | |
Primary | C-terminal cross-linked type 1 collagen terminal peptide (CTX) | Bone resorption marker, CTX were determined at baseline, 6 and 12 months after surgery | up to 12 months | |
Primary | Visual analog scale (VAS) back | The VAS score for back pain were determined at baseline, 6 and 12 month. Use a ruler about 10cm long, one side is marked with "0" and the other "10" respectively. A score of 0 indicates no pain, 10 indicates the most unbearable pain. | up to 12 months | |
Secondary | The Roland-Morris Disability Questionnaire | The Roland-Morris Disability Questionnaire is scored by 24 adding up the number of items checked "yes" on different low back pain-related daily activity disabilities. Total scores range from 0 to 24, with higher scores 24 indicating a higher level of disability related to low back pain and lowest 0 represents no back pain. | up to 12 month | |
Secondary | The QUALEFFO-31 Questionnaire | The Quality of Life Questionnaire of the European Foundation for Osteoporosis-31 (QUALEFFO-31), which contains three domains including pain, physical function, and mental function. This scale is assessed on a scale of 0 to 100, with 0 indicating the highest QoL and 100 the lowest. | up to 12 month | |
Secondary | The EQ-5D Questionnaire | The EuroQol five-dimension (EQ-5D) questionnaire evaluates health status consisting five dimensions: mobility, selfcare, performance of usual activities, pain or discomfort, and anxiety or depression. After conversion, the index was between 0 and 1.0 (minimum score: 0, indicating worst health state; full score:1.0, indicating full health). | up to 12 month | |
Secondary | New fracture rate | New fracture rate containing vertebral fracture and non-vertebral fracture was assessed at 12 month after surgery. The lowest score was 0, the highest score was 100%. The lower score 0 represents no secondary fracture. | up to 12 month | |
Secondary | Complications | Complications including cage subsidence, pedicle screw loosening, infection, peripheral nerve injury, and recurrent symptoms were assessed. | up to 12 month | |
Secondary | Adverse events | The main adverse events including deep venous thrombosis, pneumonia, acute renal failure, pulmonary embolism, myocardial infarction, influenza, transfer to intensive care unit, joint pain, headache, nausea, osteonecrosis of the jaw, atypical femoral fracture and rash. | up to 12 month |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04754711 -
Interest of Nutritional Care of Children With Sickle Cell Disease on Bone Mineral Density and Body Composition
|
N/A | |
Active, not recruiting |
NCT05066477 -
A Clinical Trial Investigating the Effect of Salmon Bone Meal on Bone Mass Among Osteopenic Women
|
N/A | |
Terminated |
NCT01902186 -
Bone Mineral Density Changes in HIV-positive Females With Osteopenia Switching to Raltegravir
|
Phase 4 | |
Completed |
NCT01439139 -
Bone UltraSonic Scanner (BUSS): Validation Study
|
N/A | |
Not yet recruiting |
NCT01397838 -
Safety Study of an Oral Pro-boneTM, Administered to Post Menopausal Osteopenic Women
|
Phase 1 | |
Completed |
NCT01222026 -
Systematic Treatment After Successful Surgical Treatment for Primary Hyperparathyroidism With Strontium Ranelate
|
Phase 4 | |
Completed |
NCT01152580 -
Melatonin Osteoporosis Prevention Study
|
Phase 1 | |
Completed |
NCT00789425 -
Investigating the Effect of Standardized Olive Extract on Bone Turnover Markers in Postmenopausal Women
|
Phase 2 | |
Completed |
NCT00655681 -
Prevention of Post Operative Bone Loss in Children
|
N/A | |
Completed |
NCT00463268 -
Osteoporosis Prevention With Low Dose Alendronate
|
Phase 3 | |
Completed |
NCT00798473 -
Zoledronate for Osteopenia in Pediatric Crohn's
|
Phase 3 | |
Active, not recruiting |
NCT00076050 -
Using Soy Estrogens to Prevent Bone Loss and Other Menopausal Symptoms
|
Phase 3 | |
Completed |
NCT00226031 -
Optimal Management of Women With Wrist Fractures
|
N/A | |
Enrolling by invitation |
NCT04752098 -
A Study to Assess Metabolic Bone Disease of Prematurity Using an Acoustic Method
|
N/A | |
Completed |
NCT04720833 -
Effect of Dried Plum on Bone and Markers of Bone Status in Men
|
N/A | |
Recruiting |
NCT05541432 -
Finding the Optimal Resistance Training Intensity For Your Bones
|
N/A | |
Active, not recruiting |
NCT05405894 -
Efficacy of Zoledronic Acid to Prevent Bone Loss Following Denosumab Discontinuation
|
||
Completed |
NCT05457036 -
Evaluation of the Effect of Spry Belt Treatment on Bone Turnover Marker Profile
|
N/A | |
Completed |
NCT04040010 -
The Effects of Bovine Colostrum in Bone Metabolism in Humans
|
N/A | |
Completed |
NCT02731820 -
Efficacy of Potassium Citrate in the Treatment of Postmenopausal Osteopenia
|
N/A |